Back to Journals » Drug Design, Development and Therapy » Volume 8

Profile of gantenerumab and its potential in the treatment of Alzheimer’s disease [Corrigendum]

Authors Novakovic D, Feligioni M, Scaccianoce S, Nisticò R, Piccinin S, Mercuri NB, Nicoletti F, Caruso A, Schepisi C, Errico F

Received 6 December 2013

Accepted for publication 6 December 2013

Published 21 May 2014 Volume 2014:8 Pages 569—570

DOI https://doi.org/10.2147/DDDT.S58818



Novakovic D, Feligioni M, Scaccianoce S, et al. Drug Des Devel Ther. 2013;7:1359–1364.

On page 1362, left hand column, last sentence under Functional studies:

The effects of gantenerumab on cognitive assessment in the Morris water maze test were inconclusive, as both wild-type and transgenic AD mice injected with vehicle displayed impairment of learning, which might be ascribed to stress conditions caused by weekly intracerebroventricular injections. Importantly, neurological or motor impairments were not detected even after 5 months of treatment.24

Should read as:

The effects of gantenerumab on cognitive assessment in the Morris water maze test were inconclusive, as both wild-type and transgenic AD mice injected with vehicle displayed impairment of learning, which might be ascribed to stress conditions caused by weekly intravenous injections. Importantly, neurological or motor impairments were not detected even after 5 months of treatment.24

Read the original article

Creative Commons License © 2014 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.